A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis

Abstract

The molecular mechanism underlying gastric cancer (GC) invasion and metastasis is still poorly understood. In this study, we tried to investigate the roles of CXCR4 and CXCR2 signalings in gastric cancer metastasis. A highly invasive gastric cancer cell model was established. Chemokines receptors were profiled to search for the accountable ones. Then the underlying molecular mechanism was investigated using both in vitro and in vivo techniques, and the clinical relevance of CXCR4 and CXCR2 expression was studied in gastric cancer samples. CXCR4 and CXCR2 were highly expressed in a high invasive gastric cancer cell model and in gastric cancer tissues. Overexpression of CXCR4 and CXCR2 was associated with more advanced tumor stage and poorer survival for GC patients. CXCR4 and CXCR2 expression strongly correlated with each other in the way that CXCR2 expression changed accordingly with the activity of CXCR4 signaling and CXCR4 expression also changed in agreement with CXCR2 activity. Further studies demonstrated CXCR4 and CXCR2 can both activated NF-κB and STAT3 signaling, while NF-κBp65 can then transcriptionally activate CXCR4 and STAT3 can activate CXCR2 expression. This crosstalk between CXCR4 and CXCR2 contributed to EMT, migration and invasion of gastric cancer. Finally, Co-inhibition of CXCR4 and CXCR2 is more effective in reducing gastric cancer metastasis. Our results demonstrated that CXCR4 and CXCR2 cross-activate each other to promote the metastasis of gastric cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. 1

    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.

  2. 2

    Yang K, Lu ZH, Zhang WH, Liu K, Chen XZ, Chen XL et al. Comparisons between different procedures of no. 10 lymphadenectomy for gastric cancer patients with total gastrectomy. Medicine 2015; 94: e1305.

  3. 3

    Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS . Chemokines in tumor progression and metastasis. Oncotarget 2013; 4: 2171–2185.

  4. 4

    Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH . Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011; 22: 2267–2276.

  5. 5

    Wei ZW, Xia GK, Wu Y, Chen W, Xiang Z, Schwarz RE et al. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Lett 2015; 359: 335–343.

  6. 6

    Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013; 49: 219–230.

  7. 7

    Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W . CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 2016; 35: 816–826.

  8. 8

    Yao C, Li P, Song H, Song F, Qu Y, Ma X et al. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma. Mol Neurobiol 2015; 53: 3948–3953.

  9. 9

    Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A . CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell 2014; 25: 566–582.

  10. 10

    Bertran E, Caja L, Navarro E, Sancho P, Mainez J, Murillo MM et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 2009; 21: 1595–1606.

  11. 11

    Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H et al. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett 2014; 354: 417–426.

  12. 12

    Fujita T, Chiwaki F, Takahashi RU, Aoyagi K, Yanagihara K, Nishimura T et al. Identification and characterization of CXCR4-positive gastric cancer stem cells. PLoS One 2015; 10: e0130808.

  13. 13

    Yang J, Richmond A . The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004; 9: 846–855.

  14. 14

    Naschberger E, Croner RS, Merkel S, Dimmler A, Tripal P, Amann KU et al. Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 2008; 123: 2120–2129.

  15. 15

    Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006; 66: 7701–7707.

  16. 16

    Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007; 26: 4679–4688.

  17. 17

    Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 2009; 100: 1755–1764.

  18. 18

    Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 2009; 125: 2586–2594.

  19. 19

    Xiang JY, Hurchla MA, Luker K, Douglas G, Romagnoli B, Chevalier E et al. Combination of a novel CXCR4 antagonist with chemotherapy reduces breast cancer bone metastatic tumor burden. Cancer Res 2014; 74 (Suppl 19): 1114 abstract 1114.

  20. 20

    Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165–178.

  21. 21

    Borthakur G, Nagler A, Ofran Y, Rowe JM, Altman JK, Frankfurt O et al. BL-8040, a peptidic CXCR4 antagonist, induces leukemia cell death and specific leukemia cell mobilization in relapsed/refractory acute myeloid leukemia patients in an ongoing phase IIa clinical trial. Blood 2014; 124: 950 abstract.

  22. 22

    Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 2014; 20: 2581–3588.

  23. 23

    Becker PS, Foran JM, Altman JK, Yacoub A, Castro JE, Sabbatini P et al. Targeting the CXCR4 pathway: safety, tolerability and clinical activity of Ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed/refractory acute myeloid leukemia. Blood 2014; 124: 386 abstract.

  24. 24

    Borsig L, Wolf MJ, Roblek M, Lorentzen A, Heikenwalder M . Inflammatory chemokines and metastasis-tracing the accessory. Oncogene 2014; 33: 3217–3224.

  25. 25

    Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev 2013; 24: 41–49.

  26. 26

    Tie J, Pan YL, Zhao LN, Wu KC, Liu J, Sun SR et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. Plos Genet 2010; 6: e1000879.

  27. 27

    Teicher BA, Fricker SP . Cxcl12 (Sdf-1)/Cxcr4 pathway in cancer. Clin Cancer Res 2010; 16: 2927–2931.

  28. 28

    Waugh DJJ, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735–6741.

  29. 29

    Grivennikov SI, Karin M . Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11–19.

  30. 30

    Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z et al. CXCR2/CXCL5 axis contributes to epithelial mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3 beta/Snail signaling. Cancer Lett 2015; 358: 124–135.

  31. 31

    Liu LP, Lin CY, Liang WJ, Wu S, Liu AB, Wu JH et al. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma. Gut 2015; 64: 26–36.

  32. 32

    Siewert JR, Bottcher K, Stein HJ, Roder JD . Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449–461.

  33. 33

    Roussos ET, Condeelis JS, Patsialou A . Chemotaxis in cancer. Nat Rev Cancer 2011; 11: 573–587.

  34. 34

    Saintigny P, Massarelli E, Lin S, Ahn YH, Chen YL, Goswami S et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 2013; 73: 571–582.

  35. 35

    An HM, Xu L, Chang Y, Zhu Y, Yang YF, Chen L et al. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer 2015; 51: 1953–1961.

  36. 36

    Li Z, Wang Y, Dong SW, Ge CL, Xiao YB, Li RL et al. Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro. Cytokine 2014; 69: 6–13.

  37. 37

    Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J et al. HIF-1 and NF-kappa B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007; 26: 7333–7345.

  38. 38

    Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH . Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells (vol 287, pg 12132, 2012). J Biol Chem 2012; 287: 19336–19336.

  39. 39

    Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 2014; 6: 237ra267.

  40. 40

    Steele CW, Karim SA, Leach JD, Bailey P, Upstill-Goddard R, Rishi L et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 2016; 29: 832–845.

  41. 41

    Pozzobon T, Goldoni G, Viola A, Molon B . CXCR4 signaling in health and disease. Immunol Lett 2016; 177: 6–15.

  42. 42

    Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L et al. A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. Cancer Lett 2016; 370: 100–107.

  43. 43

    Mukherjee S, Manna A, Bhattacharjee P, Mazumdar M, Saha S, Chakraborty S et al. Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells. Oncogene 2016; 35: 4937–4948.

  44. 44

    Fidler IJ . Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651–2660.

  45. 45

    Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259–273.

  46. 46

    Wang SM, Tie J, Wang WL, Hu SJ, Yin JP, Yi XF et al. POU2F2-oriented network promotes human gastric cancer metastasis. Gut 2015; 65: 1427–1438.

  47. 47

    Wang H, Guan X, Tu Y, Zheng S, Long J, Li S et al. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res 2015; 34: 59.

  48. 48

    Yang G, Rosen DG, Liu GZ, Yang F, Guo XQ, Xiao X et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010; 16: 3875–3886.

  49. 49

    Liu H, Liu YD, Liu WS, Zhang WJ, Xu JJ . EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun 2015; 6: 8494.

  50. 50

    Maxwell PJ, Neisen J, Messenger J, Waugh DJJ . Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget 2014; 5: 4895–4908.

  51. 51

    Tsai TYC, Choi YS, Ma WZ, Pomerening JR, Tang C, Ferrell JE . Robust, tunable biological oscillations from interlinked positive and negative feedback loops. Science 2008; 321: 126–129.

  52. 52

    Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD et al. NF-kappa B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003; 278: 21631–21638.

  53. 53

    Manu KA, Shanmugam MK, Rajendran P, Li F, Ramachandran L, Hay HS et al. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer 2011; 10: 107.

  54. 54

    Nguyen-Jackson H, Panopoulos AD, Zhang H, Li HS, Watowich SS . STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 2010; 115: 3354–3363.

  55. 55

    Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, Navarro E et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 2013; 58: 2032–2044.

  56. 56

    Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012; 22: 656–667.

  57. 57

    Hu JJ, Jo MJ, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL . Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci USA 2011; 108: 15984–15989.

  58. 58

    Garcia-Irigoyen O, Latasa MU, Carotti S, Uriarte I, Elizalde M, Urtasun R et al. Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis. Hepatology 2015; 62: 166–178.

  59. 59

    Heinrich EL, Lee W, Lu J, Lowy AM, Kim J . Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med 2012; 10: 68.

  60. 60

    Feng YF, Guo H, Yuan F, Shen MQ . Lipopolysaccharide promotes choroidal neovascularization by up-regulation of CXCR4 and CXCR7 expression in choroid endothelial cell. PLoS ONE 2015; 10: e0136175.

  61. 61

    Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J et al. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29: 709–722.

  62. 62

    Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res 2015; 75: 4985–4997.

  63. 63

    Ko YS, Cho SJ, Park J, Kim Y, Choi YJ, Pyo JS et al. Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression. Br J Cancer 2015; 113: 1186–1196.

  64. 64

    Wang YW, Chen X, Gao JW, Zhang H, Ma RR, Gao ZH et al. High expression of cAMP-responsive element-binding protein 1 (CREB1) is associated with metastasis, tumor stage and poor outcome in gastric cancer. Oncotarget 2015; 6: 10646–10657.

  65. 65

    Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 2006; 66: 2181–2187.

  66. 66

    Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 2013; 132: 276–287.

Download references

Acknowledgements

We acknowledge the use of NCBI GEO database, such as GSE29272, GSE15459 and GSE62254. This study was supported by the National Natural Science Foundation of China (No. 81272643 and No. 81272637) and ‘3 & 3’ project of The First Affiliated Hospital of Sun Yat-sen University.

Author contributions

CHZ, ZX, GGX and ZWW designed the study. ZX, ZJZ, ZWW, XHZ, GKX and JTZ performed the study. ZX, CHZ, WC, RES, RAB, NA and YLH analyzed the data and wrote the paper.

Author information

Correspondence to C-H Zhang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xiang, Z., Zhou, Z., Xia, G. et al. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene 36, 5122–5133 (2017) doi:10.1038/onc.2017.108

Download citation

Further reading